A Phase I study of an HLA-DPB1*0401-restricted T cell receptor targeting MAGE-A3 for patients with metastatic cancers

Lu, Yong-Chen; Parker, Linda L.; Lu, Tangying; Zheng, Zhili; Yao, Xin; Robbins, Paul F.; Bruggen, Pierre van der; Klebanoff, Christopher A.; Hinrichs, Christian S.; Goff, Stephanie L.; Sherry, Richard M.; Kammula, Udai S.; Yang, James Chih‐Hsin; Rosenberg, Steven A.

doi:10.1186/2051-1426-3-s2-p158

Cited by 11 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NCT02111850). 66 We hypothesise that CTAs may be expressed more frequently in the chemoresistant cells selected after neoadjuvant therapy, owing to their association with features that promote clonal selection (primitive phenotype, high proliferation, and CIN). Features of high proliferation, evasion of apoptosis, and a primitive/stem-like state, which is considered to be an epithelial-mesenchymal transition state, perhaps confer chemoresistance to these cells, as is evident in multiple myeloma.…”

Section: Discussionmentioning

confidence: 99%

Expression of MAGE‐A and NY‐ESO‐1 cancer/testis antigens is enriched in triple‐negative invasive breast cancers

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Expression of MAGE‐A and NY‐ESO‐1 cancer/testis antigens is enriched in triple‐negative invasive breast cancers

et al. 2018

View full text Add to dashboard Cite

show abstract

“…MAGE derived peptides can be recognized cytolytic T lymphocytes and cause tumor rejection, making MAGE antigens as idea targets. A series of clinical trials with MAGE antigens are in progress [3,4]. Previous studies have identified several MAGE members up-regulated in gastric cancers and associated with more aggressive phenotypes and poor clinical outcomes [5][6][7].…”

mentioning

confidence: 99%

Identification of MAGEA12 as a prognostic outlier gene in gastric cancers

Wu¹,

Wang²,

Shen³

2017

neo

View full text Add to dashboard Cite

Melanoma antigen (MAGE) family genes are frequently over-expressed in a subset population of multiple cancers, and serve as idea therapeutic targets; however, their distribution pattern in gastric cancers has not yet been evaluated. In this study, we first performed a cancer outlier profile analysis (COPA) on a series of public gene expression datasets of gastric cancer, and identified MAGEA12 showing a significant outlier expression model reproducibly. We further in silico validated that MAGEA12 outlier over-expression were associated with poor clinical outcome using six microarray datasets from GEO database. We then experimentally detected the MAGEA12 expression in an independent cohort of gastric cancer samples by immunohistochemistry, and showed that over-expression of MAGEA12 in a subset of cancers was associated with later stage and reduced survival; furthermore, MAGEA12 was an independent prognostic factor in an outlier manner. Our results indicate that MAGEA12 is a novel prognostic outlier gene in gastric cancers and patterns of MAGE expression may inform individualized targeted immunotherapies.

show abstract

“…Other TSAs considered in TCR therapy include mutant antigens and neoantigens, most of which are safe targets due to their exclusive expression in tumor cells. TCR-engineered autologous T-cell therapy has demonstrated significant preclinical response in multiple myeloma [ 164 ], melanoma [ 165 ], and other solid tumors [ 166 , 167 , 168 ]. The U.S. FDA recently approved the first T cell receptor (TCR) therapeutic (tebentafusp) for patients with HLA-A*02:01-positive Uveal melanoma [ 169 ].…”

Section: Adoptive Cell Therapymentioning

confidence: 99%

Emerging Trends in Immunotherapy for Cancer

et al. 2022

View full text Add to dashboard Cite

Recent advances in cancer immunology have enabled the discovery of promising immunotherapies for various malignancies that have shifted the cancer treatment paradigm. The innovative research and clinical advancements of immunotherapy approaches have prolonged the survival of patients with relapsed or refractory metastatic cancers. Since the U.S. FDA approved the first immune checkpoint inhibitor in 2011, the field of cancer immunotherapy has grown exponentially. Multiple therapeutic approaches or agents to manipulate different aspects of the immune system are currently in development. These include cancer vaccines, adoptive cell therapies (such as CAR-T or NK cell therapy), monoclonal antibodies, cytokine therapies, oncolytic viruses, and inhibitors targeting immune checkpoints that have demonstrated promising clinical efficacy. Multiple immunotherapeutic approaches have been approved for specific cancer treatments, while others are currently in preclinical and clinical trial stages. Given the success of immunotherapy, there has been a tremendous thrust to improve the clinical efficacy of various agents and strategies implemented so far. Here, we present a comprehensive overview of the development and clinical implementation of various immunotherapy approaches currently being used to treat cancer. We also highlight the latest developments, emerging trends, limitations, and future promises of cancer immunotherapy.

show abstract

A Phase I study of an HLA-DPB1*0401-restricted T cell receptor targeting MAGE-A3 for patients with metastatic cancers

Cited by 11 publications

References 0 publications

Expression of MAGE‐A and NY‐ESO‐1 cancer/testis antigens is enriched in triple‐negative invasive breast cancers

Expression of MAGE‐A and NY‐ESO‐1 cancer/testis antigens is enriched in triple‐negative invasive breast cancers

Identification of MAGEA12 as a prognostic outlier gene in gastric cancers

Emerging Trends in Immunotherapy for Cancer

Contact Info

Product

Resources

About